

Atelvia - (35 mg; Tablet, Delayed Release)

| | | | |
|------------------------------|----------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | Risedronate Sodium | Innovator | Allergan |
| Dosage | 35 mg; Tablet, Delayed Release | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | Indicated for the treatment of osteoporosis in postmenopausal women. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.